Bora Completes Deal for TWi Pharmaceuticals

Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), has acquired TWi Pharmaceutical Co.Ltd, a technology-based company that specializes in development and commercialization of niche generic drugs.

The purchase of TWi Pharmaceuticals adds two manufacturing facilities and will boost Bora’s service offerings in key areas, including formulation development, sterile ophthalmic, and niche manufacturing technologies.

TWi Pharmaceuticals USA operations will remain a separate entity and be able to take advantage of Bora’s existing large-scale production capacity, while also transferring some of the commercial manufacturing of its generic and 505b2 drugs in the US to certain Bora sites.

“ … TWi has a long history of strong formulation development, as well as an impeccable quality track record,” says Bobby Sheng, CEO of Bora Pharmaceuticals. “As a result of acquiring TWi, Bora will be able to further expand on our capabilities as a full service CDMO. I’m looking forward to continuing our growth in this industry.”